Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.

Current cancer drug targets

Volumn 10, Issue 8, 2010, Pages 922-931

  Geis, Nicolas ^a   Zell, Stefanie ^b   Rutz, Renate ^b   Li, Wenhan ^b   Giese, Thomas ^b   Mamidi, Srinivas ^b   Schultz, Stefan ^b   Kirschfink, Michael ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD46 PROTEIN, HUMAN; CD59 ANTIGEN; CD59 PROTEIN, HUMAN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; RNA; SMALL INTERFERING RNA;

ARTICLE; CHEMISTRY; COMPLEMENT ACTIVATION; DRUG ANTAGONISM; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT ACTIVATION; FLOW CYTOMETRY; HUMANS; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84862833647     PISSN: None     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800910793357952     Document Type: Article

References (0)